BioWorld

Sep. 14, 2007

Isis Gets $45M Up Front In Deal With Ortho On Diabetes Drugs

Four months after licensing a preclinical, second-generation antisense drug for high cholesterol to Bristol-Myers Squibb Co. in a deal worth up to $192 million, Isis Pharmaceuticals Inc. is at it again. (BioWorld Today) Read More

Genmab's 'Turnaround' Year Includes More Cancer Focus

More Is More For Receptor Tyrosine Kinase Inhibitors

PTC Gets $20M Investment From Celgene For Oncology Targets

Cell Therapy Company Aldagen Adds $9M To Series C Financing

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 3, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...